Russia has taken a bold step in global cancer research with the introduction of Enteromix, a groundbreaking mRNA-based vaccine designed to fight colorectal cancer.
According to reports, Russia announced at the 10th Eastern Economic Forum in Vladivostok that the vaccine is “ready” for clinical use after successful early trials.
Developed by the National Medical Research Radiology Centre in partnership with the Engelhardt Institute of Molecular Biology, Enteromix harnesses the same mRNA technology used in COVID-19 vaccines.
However, unlike conventional chemotherapy or radiation, which often harm healthy cells, this vaccine trains the immune system to recognize and destroy tumor cells with far fewer side effects.
The vaccine contains four non-harmful viruses that activate an immune response, specifically targeting tumor destruction.
By slowing cancer cell multiplication and shrinking tumor size, Enteromix aims to improve survival rates and extend life expectancy for patients.
The first version focuses on colorectal cancer, a leading cause of cancer-related deaths worldwide.
During clinical testing on 48 patients, Enteromix produced remarkable results:
Tumor sizes shrank by 60% to 80%.
Cancer growth was halted or reversed.
Survival rates improved significantly.
Patients experienced no dangerous adverse reactions.
The vaccine proved effective across multiple treatment sessions.
Dr. Veronika Skvortsova, head of Russia’s Federal Medical and Biological Agency (FMBA), emphasized that Enteromix represents a breakthrough in personalized treatment.
Unlike one-size-fits-all therapies, the vaccine is tailored to each patient’s RNA profile, ensuring precise targeting of cancer cells.
This design allows doctors to develop doses unique to individual tumors, increasing the chances of success.
Russia’s government has pledged to make Enteromix available free of charge once it receives regulatory approval, signaling a major step in making advanced cancer treatment accessible to all social classes.
The technology is not limited to colorectal cancer. Researchers are also developing versions aimed at glioblastoma brain cancer and melanoma, raising hopes for broader applications.
Globally, other pharmaceutical leaders such as BioNTech and Moderna are pursuing mRNA cancer vaccines for pancreatic, lung, and skin cancers.
The United Kingdom has launched its Cancer Vaccine Launch Pad to support mass trials, while India is developing vaccines for breast, oral, and cervical cancers. Russia, however, has placed itself at the forefront by declaring readiness for clinical use.
Despite its promise, Enteromix still requires larger phase 2 and phase 3 clinical trials to confirm safety and effectiveness in wider patient groups.
Regulatory approvals from the Russian Ministry of Health and international health bodies will be critical before the vaccine can enter widespread medical practice.
If successful, Enteromix could revolutionize cancer treatment. Patients may one day receive customized vaccines that offer targeted protection, fewer side effects, and a better quality of life compared to current therapies.
For millions of colorectal cancer patients worldwide, Russia’s breakthrough offers not just hope, but also the possibility of a future where advanced cancer care is affordable and accessible.
The post Russia Unveils Free Cancer Vaccine appeared first on Diaspora Digital Media DDM.
